Mini-reviewNovel targeted therapeutics for metastatic castration-resistant prostate cancer
Introduction
Prostate cancer is the most common malignancy in men worldwide. In the United States, there were an estimated 186,300 new diagnoses of prostate cancer and 28,700 prostate cancer deaths in 2008, representing 25% of new cancer cases and 10% of male cancer deaths [1]. This makes prostate cancer the second leading cause of cancer death in men. While the disease can potentially be cured when localized, metastatic prostate cancer remains incurable.
Treatment of localized prostate cancer is usually centered around surgery and/or radiation therapy. However, even after definitive local therapy, approximately 30–50% of patients will have a local or distant recurrence [2], [3]. Patients with metastatic prostate cancer have a median survival of 3–7 years, and most men die of it [2]. Treatment for metastatic disease involves surgical castration or hormonal manipulation using gonadotropin-releasing hormone (GnRH) agonists, antiandrogens, or both. Although the majority of these patients initially respond to androgen deprivation therapy, all eventually progress to a state of castration-resistant prostate cancer (CRPC). Treatment options for these men are limited. Secondary hormonal manipulations, such as ketoconazole, are often used but these produce short-lived responses and do not improve survival [4]. Other acceptable approaches in these men include watchful waiting until the development of symptoms, or the initiation of cytotoxic chemotherapy. In this regard, the chemotherapeutic agent docetaxel has been shown to improve overall survival in patients with CRPC, but only by a median of 2.9 months (median survival 19.2 months versus 16.3 months using mitoxantrone, P = .004) [5], [6]. Novel therapies for this patient population are urgently needed.
Since the approval of docetaxel by the Food and Drug Administration (FDA) in 2004, no new anti-cancer therapies have entered the market for the treatment of metastatic CRPC. On the other hand, the number of agents for CRPC in various stages of clinical development is higher than ever before. This has been made possible due to our accelerated understanding of the biological and molecular mechanisms underpinning prostate cancer growth and spread, which has fueled an expansion in research on new therapeutic approaches. This review will highlight novel targeted therapies that have emerged for CRPC in the last 5 years, focusing on the mechanism of action and developmental status of some key clinical compounds that have reached phase II and III clinical trials (Table 1). Advances in chemotherapeutic drugs, hormonal agents, and bisphosphonates will not be discussed herein.
Section snippets
Targeted treatments
Although a prostate cancer stem cell has yet to be conclusively demonstrated, prostate cancer clearly progresses from an androgen-dependent tumor (with features similar to the luminal differentiated glands of the prostate) to a castration-resistant tumor that has features of adult stem cells, including anti-apoptotic mechanisms, chemotherapy resistance, and reliance on nonhormonal signaling pathways [7]. Candidate prostate cancer progression pathways under investigation include epidermal growth
Immunotherapy
Entraining the immune system to overcome tumor-induced tolerance is the goal of nearly every cancer vaccine program, and active immunotherapy with vaccination against tumor antigens has been pursued in many different cancer models. A variety of approaches have been employed including: dendritic cell-based therapies; novel adjuvants such as Bacille Calmette-Guérin (BCG), granulocyte-monocyte colony-stimulating factor (GM-CSF), and viral carriers; single-antigen or whole cell vaccines; and
Conclusion
Although its benefits are modest, docetaxel chemotherapy remains the standard of care for the treatment of metastatic CRPC in 2009. As such, docetaxel has become the backbone of current drug development strategies in CRPC, either as the comparator arm in clinical trials or as the foundation on which novel targeted agents are added. To this end, the most promising agents in the pre-chemotherapy setting are likely to be docetaxel-bevacizumab, docetaxel-atrasentan, and sipuleucel-T. In addition,
Conflict of interest
ESA indicates no financial or other conflicts of interest. MAC has served as a consultant for Sanofi-Aventis, Abbott, Pfizer, Genentech, AstraZeneca, Novartis, Wyeth, and Cougar Biotechnology (now Johnson & Johnson); he has received honoraria from Sanofi-Aventis and Abbott. MAE has served as a consultant for Sanofi-Aventis, Ipsen, Celgene, and Centocor (now Centocor Ortho Biotech).
Funding
None.
References (157)
- et al.
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
J. Biol.
(2004) - et al.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Lancet
(2008) - et al.
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
Urology
(1999) - et al.
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale
Urol. Oncol.
(2006) - et al.
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
Eur. Urol.
(2008) - et al.
Thalidomide
Lancet
(2004) - et al.
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer
Urology
(2004) - et al.
Urology
(1999) - et al.
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
Ann. Oncol.
(2009) - et al.
In vivo evaluation of AT-101 (R-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration
Neoplasia
(2007)
Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Lancet
Expression of endothelin receptor a associated with prostate cancer progression
J. Urol.
Osteoprotegerin and rank ligand expression in prostate cancer
Urology
Cancer statistics, 2008
CA Cancer J. Clin.
Natural history of progression after PSA elevation following radical prostatectomy
JAMA
Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
JAMA
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial
J. Clin. Oncol.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
New Engl. J. Med.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
J. Clin. Oncol.
Mechanisms of androgen-refractory prostate cancer
New Engl. J. Med.
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
Cancer Res.
Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma
Expert Opin. Ther. Targets
The phosphatidylinositol 3-kinase AKT pathway in human cancer
Nat. Rev. Cancer
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP-mTOR
Proc. Natl. Acad. Sci. USA
An inhibitor of mTOR reduces neoplasia and normalizes p70/s6 kinase activity in PTEN +/− mice
Proc. Natl. Acad. Sci. USA
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Oncogene
The TOR pathway: a target for cancer therapy
Nat. Rev. Cancer
Targeting the mTOR signaling network for cancer therapy
J. Clin. Oncol.
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
New Engl. J. Med.
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
J. Clin. Oncol.
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
J. Clin. Oncol.
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells
Cancer Res.
Phase I trial of RAD001 and docetaxel in castration resistant prostate cancer with FDG-PET assessment of RAD001 activity
J. Clin. Oncol.
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate
Urology
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480
Clin. Cancer Res.
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer
Clin. Cancer Res.
Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production
Clin. Cancer Res.
The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006
J. Clin. Oncol.
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Nat. Rev. Cancer
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer
Clin. Cancer Res.
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
J. Clin. Oncol.
A phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic androgen-independent prostate cancer
J. Clin. Oncol.
Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer
J. Clin. Oncol.
Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma: Preliminary results of a phase II trial
J. Clin. Oncol.
Sorafenib in advanced clear-cell renal-cell carcinoma
New Engl. J. Med.
Sorafenib in advanced hepatocellular carcinoma
New Engl. J. Med.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
Clin. Cancer Res.
Cited by (74)
Zinc, ω-3 polyunsaturated fatty acids and vitamin D: An essential combination for prevention and treatment of cancers
2021, BiochimieCitation Excerpt :Vitamin D deficiency has been described as an unrecognized epidemic among both children and adults in the United States and it has been associated with increased risks of cancers, cardiovascular disease and a number of other serious diseases [256]. For example, epidemiological studies have shown an increased risk of prostate cancer in those men with vitamin D deficiency [257]. A confusing factor in the recognition of vitamin D as essential for general good health as well as in cancer prevention, is the problem of excessive sun exposure.
Distinct biological responses of metastatic castration resistant prostate cancer cells upon exposure to G-quadruplex interacting naphthalenediimide derivatives
2019, European Journal of Medicinal ChemistryProstate cancer health disparities: An immuno-biological perspective
2018, Cancer LettersCitation Excerpt :Apparently, through activation of this pathway, AA men have a higher risk of PCa than EA men. In advanced PCa, alterations of components of the PI3K/Akt/mTOR signaling pathway, including mutations in tumor suppressor genes such as PTEN, are more frequent and correlate with high Gleason scores, advanced stages, and resistance to chemotherapy [28,78]. These alterations result in activation of PI3K/Akt/mTOR signaling and accumulation of abnormalities, such as lower expression of PTEN, a negative regulator of PI3K/Akt/mTOR survival pathways.
Biodegradable brush-type copolymer modified with targeting peptide as a nanoscopic platform for targeting drug delivery to treat castration-resistant prostate cancer
2016, International Journal of PharmaceuticsSimultaneous determination of multiple androgens in mice organs with liquid chromatography tandem mass spectrometry
2015, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide [1].